{"contentid": 488417, "importid": NaN, "name": "Cancer cachexia drug Adlumiz launched in Japan", "introduction": "Privately-owned Swiss drugmaker Helsinn has announced the launch of Adlumiz (anamorelin) for the treatment of cancer cachexia in malignant non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer in Japan, through its partner Ono Pharmaceutical.", "content": "<p>Privately-owned Swiss drugmaker Helsinn has announced the launch of Adlumiz (anamorelin) for the treatment of cancer cachexia in malignant non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer in Japan, through its partner Ono Pharmaceutical (TYO: 4528).</p>\n<p>Cancer cachexia is a complex metabolic disorder syndrome, characterized by decreased body weight and anorexia associated with cancer. It can affect up to 80% of patients with advanced cancer.</p>\n<p>Adlumiz has shown efficacy in increasing body weight, muscle mass, as well as appetite in cancer cachexia patients.</p>\n<p>It was approved by the Japanese Minister of Health, Labor and Welfare based on results from two clinical studies conducted in Japan in patients with cancer cachexia alongside non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer.</p>\n<p>Ono has exclusive rights to develop and commercialize the product in Japan, South Korea and Taiwan. Helsinn retains full rights in the rest of the world.</p>\n<p>Development of the drug is ongoing internationally, through two Phase III SCALA studies being conducted in the USA, European Union (EU), Russia and Australia for adult patients with advanced non-small cell lung cancer for treatment of malignancy associated weight loss and anorexia.</p>\n<p>Sergio Cantoreggi, Helsinn Group chief scientific officer, said: &ldquo;We are thrilled to see the first commercial launch of Adlumiz in Japan and look forward to updating the market on the Phase III SCALA studies taking place in the USA, EU, Russia and Australia which we hope will enable us to bring the treatment to more and more patients globally.&rdquo;</p>", "date": "2021-04-21 16:31:00", "meta_title": NaN, "meta_keywords": "cancer, cachexia, Japan, Adlumiz, lung, cell, non-small, Helsinn, treatment, patients, gastric, pancreatic, colorectal, launch, drug, launched, drugmaker", "meta_description": "Privately-owned Swiss drugmaker Helsinn has announced the launch of Adlumiz (anamorelin) for the treatment of cancer cachexia in malignant non-small cell lung c", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-21 15:57:08", "updated": "2021-04-21 17:02:45", "access": NaN, "url": "https://www.thepharmaletter.com/article/cancer-cachexia-drug-adlumiz-launched-in-japan", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "helsinn_large.jpg", "image2id": "helsinn_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Oncology, Toxicology", "topic_tag": "Asia Pacific, Focus On, Product Launch", "geography_tag": "Japan, Switzerland", "company_tag": "Helsinn Group, Ono Pharmaceutical", "drug_tag": "Adlumiz, anamorelin", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-21 16:31:00"}